1. Chemistry
General
Melting points were determined with a Yanaco MP-J8 micro melting point apparatus.
1 H and 13 C NMR spectra were recorded on a JEOL JNM-LA400, JEOL JNM-AL400 or JNM-AL300 spectrometer. Chemical shifts were reported in the scale relative to CDCl3 as an internal reference. FAB-MS was taken on a Hitachi M-80B or JEOL JMS-700. MALDI-TOF/MS was taken on Bruker Daltonics Reflex III with matrix dimer and angiotensin I as internal standards. ESI-MS was taken on Bruker microTOF-QII-RSL. IR spectra were measured on a Thermo
Nicolet AVATAR 370 FT-IR. Column chromatography was performed with silica gel 60 (40-100 µm) purchased from Kanto Chemical Co. Dehydrated stabilizer-free tetrahydrofuran (THF), dehydrated dichloromethane, and dehydrated dimethylformamide (DMF) were purchased from Kanto Chemical Co., and used as received. The purity of IM-31, 38, 39, 44, 68, (R)-75, (S)-75, 78, and 79 was checked by HPLC. The purity of other IM derivatives was assessed by elemental analysis.
Synthesis of indolylmaleimide derivatives Synthesis of indolylmaleimide derivatives having various alkylamino substituents
Syntheses of IM-20, 12, and 17 have already been reported. 1 Except for IM-38, IM derivatives having various alkylamino substituents were similarly synthesized from IM-3 or IM-4 according to the reported procedure (Scheme S1). 1 Typical synthetic procedures are described below for IM-38 and IM-57.
Scheme S1
3-Amino-1-methyl-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (IM-38)
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To a solution of sodium azide (37.1 mg, 0.57 mmol) in DMSO (1.5 mL) was added IM-4 (31.9 mg, 0.1 mmol) at room temperature. The reaction mixture was stirred for 9 h, and then evaporated to dryness. The residue was taken up in brine and extracted with AcOEt. The organic layer was dried over MgSO4, and concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography to give IM-38 (8. 
3-(Benzylamino)-1-methyl-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (IM-57)
To a solution of IM-3 (191 mg, 0.70 mmol) in THF (3.5 mL) was added benzylamine (379 µL, 3.5 mmol). The mixture was stirred at 50 °C for 30 h, then filtered through Florisil, and the filtrate was evaporated. The residue was purified by silica gel column chromatography (hexane/AcOEt = 1/0 ~ 4/1) to give IM-57 (227 mg, 94%) as a yellow powder; mp 170-171 °C; IR (neat, cm 
3-(Dimethylamino)-1-methyl-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (IM-39)
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Synthesized from IM-3 (quant. 306.12; found 306.00; purity >98% (HPLC). 
Synthesized from IM-3 (71%) as a yellow solid; mp 139-141 °C; IR (neat, cm 
Synthesized from IM-4 (63%) as an orange solid; mp 119-121 °C; IR (neat, cm 
Synthesized from IM-4 (68%) as an orange solid; IR (neat, cm 
Synthesized from IM-4 (70%) as an orange solid; IR (neat, cm 
Synthesized from IM-4 (54%) as an orange solid; IR (neat, cm 
Synthesized from IM-4 (89%) as an orange solid: mp 133-136 °C; IR (neat, cm 
Synthesized 
Synthesized from IM-4 (66%) as an orange solid; mp 136-139 °C; IR (neat, cm 
Synthesized from IM-3 (82%) as a red amorphas; IR (neat, cm 
Synthesized from IM-4 (82%) as an orange solid; mp 120-122 °C; IR (neat, cm 
Synthesis of indolylmaleimide derivatives having various substituents on the maleimide ring Scheme S2
Conditions: (a) K2CO3, MeI, DMF (71%); (b) propylamine, THF (91%); (c) TFA, CH2Cl2 (75%); (d) R-X, K2CO3, DMF.
As shown in Scheme S2, various substituents were introduced into the maleimide ring. Typical synthetic procedures to obtain IM-83 are described below.
To a solution of 1 2 (40.8 mg, 76.5 µmol) in DMF (1.0 mL) was added potassium carbonate (31.7 mg, 229.5 µmol). The mixture was stirred for 30 min, and then methyl iodide (14.3 µL, 229.5 µmol) was added to it at 0 °C.
The reaction mixture was allowed to warm to room temperature, stirred for 1 h, quenched with brine, and extracted with CH2Cl2. The organic solution was dried over MgSO4, and concentrated under reduced pressure. 
To a solution of 2 (305 mg, 557 µmol) in THF (5.5 mL) was added n-propylamine (1.38 mL, 16.7 mmol). The mixture was stirred at 30 °C for 2.5 h, and then evaporated. 
To a solution of IM-44 (265 mg, 504 µmol) in CH2Cl2 (5 mL) was added TFA (3.86 mL, 50.4 mmol) at 0 °C.
The reaction mixture was allowed to warm to room temperature, stirred for 2 h, quenched with brine, and extracted with CH2Cl2. The organic solution was dried over MgSO4, and concentrated under reduced pressure. 
To a solution of 3 (10.5 mg, 37 µmol) in DMF (0. 
1-Butyl-3-(1-methyl-1H-indol-3-yl)-4-(propylamino)-1H-pyrrole-2,5-dione (IM-79)
Synthesized from 3 (92%) as an orange solid; mp 131-133 °C; IR (neat, cm 
3-(1-Methyl-1H-indol-3-yl)-4-(propylamino)-1-tridecyl-1H-pyrrole-2,5-dione (IM-78)
Synthesized from 3 (83%) as an orange solid; mp 74-77 °C; IR (neat, cm 
1-Cyclopentyl-3-(1-methyl-1H-indol-3-yl)-4-(propylamino)-1H-pyrrole-2,5-dione (IM-53)
Synthesized from 3 (99%) as an orange solid; mp 145-148 °C; IR (neat, cm 
3-(1-Methyl-1H-indol-3-yl)-1-(pentan-3-yl)-4-(propylamino)-1H-pyrrole-2,5-dione (IM-77)
Synthesized from 3 (96%) as an orange amorphas; IR (neat, cm 
1-Benzyl-3-(1-methyl-1H-indol-3-yl)-4-(propylamino)-1H-pyrrole-2,5-dione (IM-70)
Synthesized from 3 (50%) as an orange solid; mp 144-146 °C; IR (neat, cm 
Water solubility of IM derivatives
Water solubility was determined according to the reported procedure. 
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2. Biology
Cell culture
HL-60 cells were maintained in RPMI 1640 medium supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 5% fetal bovine serum (FBS). Jurkat cells were maintained in RPMI 1640 medium supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% FBS. THP-1 cells were maintained in RPMI 1640 medium supplemented with 10% FBS. NIH/3T3 cells were cultured in DMEM supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10 % FBS. All cells were grown in a humidified incubator at 37 °C under 5% CO2/95% air.
Cell death inhibition assay of IM derivatives using HL-60 cells
According to the previous report, 
Necroptosis
According to the previous report, 1 Jurkat cells (7.5 x 10 3 cells/well) were treated with Fas ligand/cycloheximide (5 µM)/Z-VAD-fmk (100 µM) in the presence or absence of cell death inhibitors for 20 h.
Cell viability was assessed with a Cell Counting Kit (Dojindo Laboratories, Japan), according to the manufacturer's protocol.
Pyroptosis
Staphylococcus aureus (Smith strain, kindly provided by Dr. Nakanishi, Kanazawa University, Kanazawa, Ishikawa, Japan) and Pseudomonas aeruginosa (JCM14847, RIKEN BioResource Center, Wako, Saitama, Japan)
in the log phase were used for infection. THP-1 (5 x 10 4 ) cells were pretreated with or without cell death inhibitors at 10 µM for 1 h, and then infected with these bacteria at a multiplicity of infection (moi) of 50 for 2 h in antibiotic-free medium in 96-well plates. The plates were briefly centrifuged to increase the interaction between cells and bacteria. At 1 h after the infection, gentamycin (50 µg/mL) was added to kill the extracellular bacteria. Cell death was determined by measuring LDH activity in culture medium with the CytoTox96
NonRadioactive Cytotoxicity Assay (Promega).
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Ferroptosis
NIH/3T3 cells were seeded onto 96-well plates (7.5 x 10 3 cells/well) and cultured overnight at 37 ºC. Then, the cells were treated with different concentrations of erastin for 24 h or TBHP for 12 h with or without a cell death inhibitor. Cell viability was assessed with a Cell Counting Kit (Dojindo Laboratories, Japan), according to the manufacturer's protocol.
NETosis Animals
Seven-to 12-week-old male C57BL/6J mice were purchased from CLEA Japan (Tokyo, Japan). All animals were maintained under specific-pathogen-free conditions in the animal facility of Tokyo University of Pharmacy and Life Sciences. All experiments using mice were approved by the Tokyo University of Pharmacy and Life 
NET formation assay
To assess human NET formation, 7.5 x 10 3 human neutrophils/well were seeded in a 96-well plate (Greiner) and treated with cell death inhibitors (IM-93, 0 to 25 µM; DFO, 100 µM; and Fer-1, 2.5 µM) at 37 ºC for 30 min.
Then, the cells were stimulated with 0.8 nM PMA for 3 h to induce NET formation. Extracellular chromatin was 
KINOMEscan screening of IM-93
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